Effects of Coenzyme Q10 Supplementation on Serum Lipoproteins, Plasma Fibrinogen, and Blood Pressure in Patients With Hyperlipidemia and Myocardial Infarction

Abstract

Background:Low plasma concentrations of coenzyme Q10 (CoQ10) have been associated with concentration of lipoproteins and other factors contributing to coronary heart diseases.Objectives:The present investigation aimed to improve the blood pressure and serum lipoproteins concentration in patients with myocardial infarction (MI) by CoQ10 supplementation.Patients and Methods:In this randomized double-blinded controlled clinical trial, 52 Iranian patients with hyperlipidemia and MI were recruited to examine the effect of CoQ10 on serum total cholesterol (TC), LDL-C, HDL-C, triglyceride (TG), LDL-C/HDL-C ratio, TC/HDL-C ratio, fibrinogen, systolic blood pressure (SBP) and diastolic blood pressure (DBP). Individuals were randomly allocated to two groups for receiving either 200 mg/d of CoQ10 or placebo for 12 weeks.Results:There were not significant differences in serum LDL-C (2.70 ± 0.31 vs. 2.70 ± 0.35 mmol/L), TC (4.47 ± 0.33 vs. 4.93 ± 0.57 mmol/L), TG (2.48 ± 0.12 vs. 2.25 ± 0.69 mmol/L), and fibrinogen (2.08 ± 0.99 vs. 38.7 ± 0.64 mg/dL) between CoQ10 and placebo groups. After 12 weeks, a significant enhancement in serum HDL-C (1.44 ± 0.18 vs. 1.14 ± 0.18 mmol/L) level was observed between groups after the supplementation (P < 0.001). A significant reduction of TC, LDL-C, and fibrinogen and a significant increase in HDL-C concentration was observed in CoQ10 group after intervention (P < 0.001). Our assessment demonstrated statistically significant differences between the two groups in SBP and DBP after intervention (P < 0.001). ANCOVA also revealed significant differences in the ratio of LDL-C/HDL-C and TC/HDL-C between the two groups (1.89 ± 0.42 vs. 2.39 ± 0.38, P = 0.002; and 3.2 ± 0.5 vs. 4.24 ± 0.66, P = 0.01, respectively). A significant reduction of LDL-C/HDL-C and TC/HDL-C was observed in CoQ10 group (P < 0.001).Conclusions:Twelve-week supplementation with CoQ10 in patients with hyperlipidemia and MI can improve blood pressure, serum HDL-C as well as LDL-C/HDL-C and TC/HDL-C ratios; therefore, it might decrease the risk of frequent MI.

The effects of coenzyme Q10 supplement on blood lipid indices and hepatic antioxidant defense system in SD rats fed a high cholesterol diet

“…In partial agreement with our results, several studies with animals have suggested that CoQ 10 significantly decreased blood triglyceride in a high fat diet fed rats or hepatic lipid concentration with no effect on plasma lipid components in atherogenic rabbits [27,28]. However, a study with humans [29] demonstrated that a CoQ 10 supplement to patients with hyperlipidemia improved serum HDL-cholesterol as well as the ratios of TC/HDL-C and LDL/HDL-C, suggesting that dietary CoQ 10 might be associated with a reduction in the risks of myocardial infarction in patients.…”

Coenzyme Q10 supplementation effects on lipid ratios in women with type 2 diabetes mellitus: A randomized, double-blind clinical trial study

“…The results reported on the effects of CoQ10 supplementation on the lipid ratios are controversial. Similar to our study, Mohseni et al 13 observed that supplementation with 200 mg per day of CoQ10 for 12 weeks in patients with hyperlipidemia, significantly decreases TC/HDL-C, and LDL-C/ HDL-C ratios. In the study of Ahmadvand et al 29 receiving CoQ10 in alloxan-induced type 1 diabetic rats, could significantly prevent the increase of atherogenic index, atherogenic coefficient, TC/ HDL-C ratio and LDL/HDL-C ratio compared with the untreated diabetic animals.…”

“…A well-known and important risk factor for incidence of CVD in patients with T2DM is dyslipidemia. Risk development of CVD in T2DM patients can be predicted through lipid ratios and AIP values [12][13][14] .…”

“…Although several studies have done to explore the effects of CoQ10 supplementation on lipid profiles in diabetes and other diseases 13,16,28 , the current study evaluated its effects on lipid ratios in women with T2DM. According to the current study findings, supplementation with CoQ10 significantly decreased atherogenic lipid ratios including TG/ HDL-C, TC/HDL-C, and LDL-C/HDL-C and significantly increased HDL ratio in the intervention group.…”

“…A welldocumented and important risk factor of CVD in patients with T2DM is dyslipidemia and insulin resistance plays an important role in the development of is 12 . The lipid ratios including TG/HDL-C, TC/ HDL-C, LDL-C/HDL-C, HDL ratio and atherogenic index of plasma (AIP) have predictive values for developing the risk of CVD in T2DM 13,14 . Since CoQ10 has positive effects on insulin resistance 15 , insulin sensitivity, lipid metabolism and dyslipidemia, some studies have suggested using glucose-lowering drugs and CoQ10 together to control levels of lipids and thus to prevent the side effects of the drugs effectively 14,16,17 .…”